OMTH Omthera Pharmaceuticals, Inc. (MM)

DALLAS, May 30, 2013 /PRNewswire/ -- Securities lawyers at Deans & Lyons announced an investigation of the board of Omthera Pharmaceuticals, Inc. (NASDAQ: OMTH) for a proposed sale to AstraZeneca. OMTH investors are encouraged to contact attorney Hamilton Lindley at 877-819-8033 or hlindley@deanslyons.com about their rights and remedies.

Although at least one analyst estimated the value could reach $15 per share before the deal was announced, OMTH stockholders will receive only $12.70 per share upon the acquisition by AstraZeneca. The investigation seeks to ensure OMTH stockholders obtain the highest price reasonably available in this buyout in addition to the disclosure of all important information.

The securities lawyers of Deans & Lyons have significant experience representing investors nationwide in representative actions involving securities at no cost to its clients.  Stockholders with concerns about this OMTH stock or anyone with information about this transaction should contact Hamilton Lindley at hlindley@deanslyons.com or 877-819-8033.

Hamilton Lindley
Deans & Lyons LLP
325 N. Saint Paul Street, Suite 1500
Dallas, TX 75201
(877) 819-8033 Toll Free
(214) 965-8500 Telephone
(214) 965-8505 Facsimile
hlindley@deanslyons.com
deanslyons.com

SOURCE Deans & Lyons LLP